Jun 27 |
Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape
|
May 29 |
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides
|
May 24 |
Cellectar Biosciences files for $300M mixed securities shelf
|
May 22 |
Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?
|
May 20 |
Cellectar Biosciences: Still Working On That Hit (Maintain Buy)
|
May 15 |
Q1 2024 Cellectar Biosciences Inc Earnings Call
|
May 15 |
Cellectar Biosciences Inc (CLRB) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
May 14 |
Cellectar Biosciences, Inc. 2024 Q1 - Results - Earnings Call Presentation
|
May 14 |
Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript
|
May 14 |
Cellectar Biosciences GAAP EPS of -$0.74 misses by $0.18
|